In addition to recently approved therapies for advanced prostate cancer, excitement is also building around two new drugs undergoing regulatory review. From the American Urological Association’s 2012 Annual Meeting in Atlanta, Dr. Neal Shore discusses enzalutamide (MDV-3100), now available as part of an Early Access Program (EAP), as well as Alpharadin (radium-223), the first isotope to not only help control pain associated with prostate cancer but also help extend survival. Dr. Shore also reminds men with earlier stage disease that while drug development and approval begin with the sickest patients, research continues to explore expanded use of these drugs and may one day be available much earlier.
See the rest here: New Drugs Under Review for Advanced Prostate Cancer Hold Great Promise